[Form 3] Evogene Ltd. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Evogene Ltd. executive Ravzin Polina, VP Finance, reported existing holdings of stock options on a Form 3. These options cover a total of 20,000 underlying ordinary shares with exercise prices ranging from 0.945 to 12.210 and expiration dates between 2032 and 2036, reflecting previously granted equity compensation that vests quarterly over four years for recent grants.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Ravzin Polina

Role VP Finance

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 3,000 shares (Direct)

Footnotes (1)

1. The options reported in this row were granted by the Issuer to the Reporting Person on March 8, 2023 and vest and become exercisable in accordance with the following schedule: 6.25% of the options vested on a quarterly basis such that all such options will be fully vested on the four-year anniversary of the grant date (i.e., by March 8, 2027). The options reported in this row were granted by the Issuer to the Reporting Person on March 5, 2025 and vest and become exercisable in accordance with the following schedule: 6.25% of the options vested on a quarterly basis such that all such options will be fully vested on the four-year anniversary of the grant date (i.e., by March 5, 2029). The options reported in this row were granted by the Issuer to the Reporting Person on March 4, 2026 and vest and become exercisable in accordance with the following schedule: 6.25% of the options vested on a quarterly basis such that all such options will be fully vested on the four-year anniversary of the grant date (i.e., by March 4, 2030).

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ravzin Polina

(Last) (First) (Middle)

5 HANAGID ST.

(Street)

RISHON LE'TZION 7548205

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2026

3. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

3a. Foreign Trading Symbol
[EVGN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Finance

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	02/03/2026	03/09/2032	Ordinary shares	3,000	$12.21	D
Stock Option (right to buy ordinary shares)	(1)	03/08/2033	Ordinary shares	1,500	$7.75	D
Stock Option (right to buy ordinary shares)	(2)	03/05/2035	Ordinary shares	6,000	$1.49	D
Stock Option (right to buy ordinary shares)	(3)	03/04/2036	Ordinary shares	9,500	$0.945	D

Explanation of Responses:

1. The options reported in this row were granted by the Issuer to the Reporting Person on March 8, 2023 and vest and become exercisable in accordance with the following schedule: 6.25% of the options vested on a quarterly basis such that all such options will be fully vested on the four-year anniversary of the grant date (i.e., by March 8, 2027).

2. The options reported in this row were granted by the Issuer to the Reporting Person on March 5, 2025 and vest and become exercisable in accordance with the following schedule: 6.25% of the options vested on a quarterly basis such that all such options will be fully vested on the four-year anniversary of the grant date (i.e., by March 5, 2029).

3. The options reported in this row were granted by the Issuer to the Reporting Person on March 4, 2026 and vest and become exercisable in accordance with the following schedule: 6.25% of the options vested on a quarterly basis such that all such options will be fully vested on the four-year anniversary of the grant date (i.e., by March 4, 2030).

	/s/ Nitsan Deutsch, attorney-in-fact	04/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)